Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder
TITANIUM
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder
2 other identifiers
interventional
876
1 country
58
Brief Summary
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Apr 2006
Shorter than P25 for phase_3
58 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2006
CompletedFirst Submitted
Initial submission to the registry
May 22, 2006
CompletedFirst Posted
Study publicly available on registry
May 24, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2007
CompletedMarch 25, 2009
March 1, 2009
May 22, 2006
March 24, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from randomization in the HAM-A total score at Day 57
Secondary Outcomes (1)
Change from randomization in CGI-S score at Day 57
Interventions
Eligibility Criteria
You may qualify if:
- Patient has a documented clinical diagnosis of Generalized Anxiety Disorder.
- Be able to understand and comply with the requirements of the study.
- Able to understand and provide written informed consent
You may not qualify if:
- Patients (female) must not be pregnant or lactating
- Current or past diagnosis of stroke or transient ischemic attack (TIA).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (58)
Research Site
Springdale, Arizona, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Encino, California, United States
Research Site
Newport Beach, California, United States
Research Site
Oceanside, California, United States
Research Site
Redlands, California, United States
Research Site
Santa Ana, California, United States
Research Site
Denver, Colorado, United States
Research Site
Norwich, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Fort Walton Beach, Florida, United States
Research Site
Gainsville, Florida, United States
Research Site
Hialeah, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Winter Park, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Smyrna, Georgia, United States
Research Site
Eagle, Idaho, United States
Research Site
Chicago, Illinois, United States
Research Site
Oak Brook, Illinois, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Topeka, Kansas, United States
Research Site
New Orleans, Louisiana, United States
Research SIte
Fall River, Massachusetts, United States
Research Site
Farmington Hills, Michigan, United States
Research Site
Ridgeland, Mississippi, United States
Research Site
St Louis, Missouri, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Cherry Hill, New Jersey, United States
Research Site
Clementon, New Jersey, United States
Research Site
Brooklyn, New York, United States
Research Site
New York, New York, United States
Research Site
Rochester, New York, United States
Research Site
Staten Island, New York, United States
Research Site
Charlotte, North Carolina, United States
Research Site
Durham, North Carolina, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Toledo, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Tulsa, Oklahoma, United States
Research Site
Portland, Oregon, United States
Research Site
Allentown, Pennsylvania, United States
Research Site
Norristown, Pennsylvania, United States
Research Site
Lincoln, Rhode Island, United States
Research Site
Memphis, Tennessee, United States
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Friendswood, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Woodstock, Vermont, United States
Research Site
Herndon, Virginia, United States
Research Site
Midlothian, Virginia, United States
Research Site
Bellevue, Washington, United States
Research Site
Seattle, Washington, United States
Research Site
Charleston, West Virginia, United States
Related Publications (3)
Montgomery SA, Locklear JC, Svedsater H, Eriksson H. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder. Int Clin Psychopharmacol. 2014 Sep;29(5):252-62. doi: 10.1097/YIC.0000000000000026.
PMID: 24394383DERIVEDStein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011 Dec;26(8):614-28. doi: 10.1002/hup.1256. Epub 2011 Dec 6.
PMID: 22143997DERIVEDKhan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011 Aug;31(4):418-28. doi: 10.1097/JCP.0b013e318224864d.
PMID: 21694613DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Willie Earley, MD
AstraZeneca
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 22, 2006
First Posted
May 24, 2006
Study Start
April 1, 2006
Study Completion
August 1, 2007
Last Updated
March 25, 2009
Record last verified: 2009-03